Amylyx Pharmaceuticals, Inc. (AMLX) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 21.67
30Y Low21.7·High21.7
P/FCF
N/A
—
5yr avg: 96.49
30Y Low96.5·High96.5
P/B Ratio
↓
4.31
+16% vs avg
5yr avg: 3.72
30Y Low1.6·High7.2
ROE
↑
-61.6%
↓+31% vs avg
5yr avg: -89.8%
30Y Low-209%·High13%
Debt/EBITDA
N/A
—
5yr avg: 0.11
30Y Low0.1·High0.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AMLX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Amylyx Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $1.1B | $258M | $1.0B | $2.5B | — | — | — |
| Enterprise Value | $936M | $922M | $182M | $864M | $2.4B | — | — | — |
| P/E Ratio → | -9.09 | — | — | 21.03 | — | — | — | — |
| P/S Ratio | — | — | 2.95 | 2.71 | 110.55 | — | — | — |
| P/B Ratio | 4.31 | 3.74 | 1.56 | 2.38 | 7.22 | — | — | — |
| P/FCF | — | — | — | 96.49 | — | — | — | — |
| P/OCF | — | — | — | 86.44 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AMLX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 2.08 | 2.27 | 108.02 | — | — | — |
| EV / EBITDA | — | — | — | 21.67 | — | — | — | — |
| EV / EBIT | — | — | — | 22.27 | — | — | — | — |
| EV / FCF | — | — | — | 80.94 | — | — | — | — |
AMLX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from 10.2% to -360.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -61.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 51.8% | 93.3% | 86.5% | — | -3683.7% | -734.4% |
| Operating Margin | — | — | -360.2% | 10.2% | -905.7% | — | -6000.8% | -950.5% |
| Net Profit Margin | — | — | -345.4% | 12.9% | -892.4% | — | -6504.6% | -1039.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -61.6% | -61.6% | -100.9% | 12.7% | -209.4% | — | — | — |
| ROA | -55.0% | -55.0% | -84.9% | 10.8% | -79.8% | -146.9% | -488.1% | -460.1% |
| ROIC | -132.2% | -132.2% | -132.3% | 10.5% | -363.9% | — | — | — |
| ROCE | -64.5% | -64.5% | -104.8% | 9.9% | -93.0% | -174.1% | -1426.4% | — |
AMLX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $227M exceeds total debt of $6M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | 0.11 | — | — | — | — |
| Net Debt / Equity | — | -0.72 | -0.46 | -0.38 | -0.17 | — | — | — |
| Net Debt / EBITDA | — | — | — | -4.16 | — | — | — | — |
| Debt / FCF | — | — | — | -15.54 | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -17.05 | -9.75 |
Net cash position: cash ($227M) exceeds total debt ($6M)
AMLX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Amylyx Pharmaceuticals, Inc.'s current ratio of 14.27x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.66x to 14.27x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.27 | 14.27 | 6.67 | 5.66 | 8.20 | 6.03 | 1.86 | 0.71 |
| Quick Ratio | 14.27 | 14.27 | 6.67 | 5.20 | 7.99 | 6.03 | 1.86 | 0.71 |
| Cash Ratio | 13.97 | 13.97 | 6.21 | 4.53 | 7.44 | 5.53 | 1.76 | 0.68 |
| Asset Turnover | — | — | 0.45 | 0.74 | 0.06 | — | 0.05 | 0.44 |
| Inventory Turnover | — | — | — | 0.66 | 0.31 | — | — | — |
| Days Sales Outstanding | — | — | 1.87 | 38.39 | 251.31 | — | — | — |
AMLX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Amylyx Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 4.8% | — | — | — | — |
| FCF Yield | — | — | — | 1.0% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $95M | $68M | $70M | $67M | $58M | $56M | $56M |
Peer Comparison
Compare AMLX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AMLXYou | $1B | -9.1 | — | — | — | — | -61.6% | -132.2% | — |
 IONS | $12B | -31.0 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 BIIB | $30B | 22.6 | 11.9 | 14.4 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 MDGL | $11B | -36.9 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 ACAD | $4B | 9.3 | 25.5 | 34.8 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRTA | $432M | -1.8 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 AGEN | $141M | -997.1 | — | — | 29.6% | -18.0% | — | — | — |
 ARVN | $457M | -5.5 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 SRRK | $5B | -13.6 | — | — | — | — | -123.1% | -201.2% | — |
 ALKS | $7B | 31.4 | 22.9 | 15.6 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 RARE | $2B | -4.1 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in AMLX 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in AMLX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs AMLX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationAMLX vs IONS — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Ionis Pharmaceuticals, Inc..
Compare NowAMLX — Frequently Asked Questions
Quick answers to the most common questions about buying AMLX stock.
What is Amylyx Pharmaceuticals, Inc.'s P/E ratio?
Amylyx Pharmaceuticals, Inc.'s current P/E ratio is -9.1x. The historical average is 21.0x.
What is Amylyx Pharmaceuticals, Inc.'s ROE?
Amylyx Pharmaceuticals, Inc.'s return on equity (ROE) is -61.6%. The historical average is -89.8%.
Is AMLX stock overvalued?
Based on historical data, Amylyx Pharmaceuticals, Inc. is trading at a P/E of -9.1x. Compare with industry peers and growth rates for a complete picture.